Autres cibles addictives (KRAS, RET, HER2, NTRK…)

D. Planchard, Simon, P. Abdayem, L. Greillier

    Research output: Contribution to journalArticlepeer-review

    Abstract

    The prognosis of advanced Non-Small Cell Lung Cancer (NSCLC) has been significantly improving ever since the discovery of oncogenic driver alterations and the implementation of targeted therapies. Today, molecular profiling, preferably by using next-generation sequencing panels as well as liquid biopsies is crucial before starting treatment in patients with non-squamous NSCLC independent of their smoking status, as well as in those with squamous NSCLC who are little or non-smokers. In this review, we present the latest evidence on the most detected driver alterations in advanced NSCLC apart from EGFR, BRAF, ALK and ROS1. A few of the novel therapies have been approved in Europe in specific settings, and many are still not reimbursed by third-party payers. This highlights the importance of encouraging patients to participate in clinical trials to gain access to innovative treatments. Translational research programs are also important to uncover mechanisms of resistance to targeted therapies and how to overcome them.

    Original languageFrench
    Pages (from-to)2S96-2S105
    JournalRevue des Maladies Respiratoires Actualites
    Volume15
    Issue number2
    DOIs
    Publication statusPublished - 1 Oct 2023

    Cite this